Subtype
Malignant Urinary Tract Neoplasm
CI-CAN-00003252Explore in graph →
507 active trials14 approved drugs29 evidence items
- NCIt
- C192668
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003252Explore in graph →
Clinical trials
1,954 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (246)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06257017 | Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma | recruiting | Phase 2 | 20 | Yung NAOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06493552 | Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors | recruiting | Phase 2 / Phase 3 | 700 | Vasgene Therapeutics, IncINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| Probiotics in Advanced Urothelial Carcinoma(IMPROVE) |
| recruiting |
| Phase 2 |
| 222 |
| Sun Yat-sen UniversityOTHER |
| 1 |
| Apr 1, 2025 |
| clinicaltrials |
| NCT04046094 | Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 12 | University of Kansas Medical CenterOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06823427 | 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 2 | 60 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT02202772 | Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder(CGC) | active not recruiting | Phase 1 / Phase 2 | 51 | Guarionex J. DecastroOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06493370 | Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer | recruiting | Phase 2 | 48 | University of Kansas Medical CenterOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT05917158 | A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma(1) | recruiting | Phase 2 | 30 | Jinling Hospital, ChinaOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT04724928 | Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer(EFFORT-MIBC) | recruiting | Phase 2 | 156 | University Hospital, GhentOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06732531 | Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 48 | Zhuhai Beihai Biotech Co., LtdINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04289779 | Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer(ABATE) | active not recruiting | Phase 2 | 46 | Deepak KilariOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04562311 | Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma | active not recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04861584 | Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects | recruiting | Phase 2 | 41 | Zhujiang HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06341400 | RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients | recruiting | Phase 1 / Phase 2 | 55 | Zhujiang HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06632262 | A Phase 2 Clinical Study of ABSK061 and ABSK043 | recruiting | Phase 2 | 202 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06639347 | A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma | recruiting | Phase 1 / Phase 2 | 90 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT06630871 | A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk. | not yet recruiting | Phase 2 | 40 | Fujian Medical University Union HospitalOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05203913 | Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer(CNN-BC) | recruiting | Phase 2 | 32 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06079112 | 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 100 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06588179 | SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt | not yet recruiting | Phase 1 / Phase 2 | 58 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06551896 | Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor | not yet recruiting | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 13, 2024 | clinicaltrials |
| NCT06528483 | Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer(preSAVE) | not yet recruiting | Phase 2 | 63 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06310369 | Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer | not yet recruiting | Phase 2 | 50 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jul 22, 2024 | clinicaltrials |
| NCT06354231 | DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05200988 | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC(Indi-Blade) | active not recruiting | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06255964 | A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 236 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Feb 13, 2024 | clinicaltrials |
| NCT03379909 | Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer(TROJAN) | recruiting | Phase 2 | 49 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05600127 | Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer(CHASIT) | recruiting | Phase 2 | 64 | Erasmus Medical CenterOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT05943379 | RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects | recruiting | Phase 2 | 85 | RemeGen Co., Ltd.INDUSTRY | 1 | Jul 13, 2023 | clinicaltrials |
| NCT04617756 | Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract(iNDUCT) | recruiting | Phase 2 | 50 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT04186013 | Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer | active not recruiting | Phase 2 | 39 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT03836352 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | active not recruiting | Phase 2 | 184 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Mar 31, 2022 | clinicaltrials |
| NCT05072600 | Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer | recruiting | Phase 2 | 54 | Peking University First HospitalOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT03179943 | Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma | active not recruiting | Phase 2 | 21 | Fox Chase Cancer CenterOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT02447549 | Study of Tumour Focused Radiotherapy for Bladder Cancer(RAIDER) | active not recruiting | Phase 2 | 345 | Institute of Cancer Research, United KingdomOTHER | 3 | Jun 9, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Apr 4, 2025source: clinicaltrials